Press "Enter" to skip to content

Morning Break: ‘Snapchat Dysmorphia’; Snoring Life Away; A Fertility First

Note that some links may require subscriptions.

Emergency room visits related to car crashes declined in states with laws banning texting while driving. (CNN)

Kingston Pharma announced a limited recall of DG™/health NATURALS baby Cough Syrup + Mucus because of possible bacterial contamination.

UPS wants to get past the front door — it’s starting a project in which nurses will vaccinate people in their homes. (Reuters)

Mississippi’s governor signed legislation banning abortion when a fetus has a detectable heartbeat, which often occurs before a woman knows she is pregnant; judges recently blocked similar legislation in Kentucky and Iowa. (Reuters)

It’s not just Instagram: “Snapchat dysmorphia” is driving a booming business in plastic surgery. (Fox News)

On average, Americans spend 145 hours a year snoring. (Withings)

The CEO of drugstore giant CVS said the company will “walk slowly” with its introduction of cannabidiol products. (CNBC)

GlaxoSmithKline announced that its anti-B cell maturation antigen antibody-drug conjugate GSK2857916 achieved a 60% response rate in the DREAMM-1 trial of patients with previously treated multiple myeloma, confirming findings from an interim analysis.

In a scientific first, fertility researchers produced a baby monkey from frozen testicular tissue, a process that could preserve fertility for pediatric cancer survivors. (The Verge)

A “victim of the pharmaceutical industry” struggles to avoid becoming an “overdose statistic.” (CBS News)

“Game of Thrones” star Emilia Clarke opens up about surviving two aneurysms. (USA Today)

A cardiologist credits a cellphone app linked to an automated blood pressure monitor with at least doubling the proportion of patients who keep high blood pressure under control. (Newsweek)

A day after pulling the plug on one investigational drug for Alzheimer’s disease, Japanese pharma giant Eisai announced the launch of a phase III trial of another anti-amyloid drug for Alzheimer’s. (Reuters)

Morning Break is a daily guide to what’s new and interesting on the Web for healthcare professionals, powered by the MedPage Today community. Got a tip? Send it to us: [email protected]